The Hematologic Malignancies Program at Duke is a leading national center for hematologic cancers, combining compassionate medical care with state-of-the-art science to improve outcomes for nearly 1,000 patients with a cancer of the blood who come to Duke each year.

Duke’s Hematologic Malignancies Program treats patients battling leukemias, lymphomas, myelomas, myeloadysplasia, aplasia, and any other blood- and lymphoid-related cancers.

Currently, there are approximately 140,000 lymphoma cases and 75,000 leukemia cases in the United States. The five-year survival rate for lymphomas ranges from 25 to 65 percent.

The most common types of adult leukemia are acute myeloid leukemia and chronic lymphocytic leukemia. Five-year survival rates for leukemia patients vary depending on risk factors but have generally improved since the 1970s with many patients now cured.